Monte Rosa Therapeutics Reports Progress on Drug Development
Company Announcements

Monte Rosa Therapeutics Reports Progress on Drug Development

Monte Rosa Therapeutics (GLUE) just unveiled an announcement.

Monte Rosa Therapeutics, Inc. has recently shared updates on the development of its drugs, MRT-2359 and MRT-6160, through a press release. Investors should note that these updates, while informative, are not considered filed under SEC regulations and do not carry the same legal weight as formal filings, nor are they integrated into earlier filings unless explicitly specified.

See more data about GLUE stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBoeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz
TheFlyMonte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler
TipRanks Auto-Generated NewsdeskMonte Rosa Enters Global License Agreement with Novartis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App